Healthcare Industry News: trastuzumab
News Release - June 4, 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel22 US Oncology Affiliated Physicians Participate in ASCO Proceedings
HOUSTON, June 4 (HSMN NewsFeed) -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.
The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.
The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.
The research found that Therapy Arm 2 (AT-->T) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cycles-->paclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to AC-->T as a standard treatment in the community. It has more peripheral neuropathy than AC-->T; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, AP-->WP was superior to AC-->T in overall survival (OS).
In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.
-- Daniel Von Hoff, M.D., Chief Scientific Officer: The Complete Phase lb Clinical Trial: A Method to Accelerate New Agent Development
-- Michael Teneriello, M.D., Co-Chair, Gynecologic Cancer Research Committee, US Oncology Research: Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum- sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer
-- Patrick Timmins, III, M.D.: Preliminary results of an open-label study to evaluate the efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with carboplatin-containing chemotherapy regimen in patients with ovarian cancer, primary peritoneal or fallopian tube carcinoma (stage I-IV) or papillary serous cancer of the uterus
-- Craig Reynolds, M.D., Co-Chair Lung Cancer Research Committee: An open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous Non-Small Cell-Lung Cancer (NSCLC)
-- Thomas Cartwright, M.D., Co-Chair, GI Cancer Research Committee: Results of a Phase II trial of cetuximab+XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
-- Craig Reynolds, M.D.: A randomized phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients (pts) with advanced (stage IIIB with pleural effusion or IV) Non-Small-Cell Lung Cancer (NSCLC)
-- Robert Raju, M.D.: Pemetrexed (P) in relapsed Small-Cell Lung Cancer (SCLC): Preliminary results of a Phase II trial
-- Don Richards, M.D., Ph.D.: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed Small-Cell Lung Cancer (SCLC)
-- J.R. Hoverman, M.D., Medical Director of Managed Care, US Oncology: Assessment of medication safety in the outpatient setting
-- Manuel Modiano, M.D.: A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer
-- Joanne Blum, M.D., Ph.D.: Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer
-- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced Non-Small Cell-Lung Cancer (NSCLC)
-- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the Treatment of Prostate Cancer and the Evolution of Bone Marrow Transplantation"
-- Marcus Neubauer, M.D., Co-Chair: Lung Cancer Research Committee: A clinical pathways project to promote evidence-based medicine in a large community oncology practice
-- Domingo Perez, M.D.: Phase II trial of carboplatin, weekly paclitaxel and biweekly bevacizumab in patients with unresectable stage IV melanoma
-- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of Life (QOL) at 36 months follow-up
-- Dr. Alexander Spira: Perifosine (P) an active agent in the treatment of patients with advanced sarcoma
-- Dr. Alexander Spira: iTARGET: A Phase II Trial to Assess the Response to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell-Lung Cancer (NSCLC) Tumors
-- Dr. Hakan Kaya: Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis
-- Dr. Hakan Kaya: Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: A Surveillance, Epidemiology, and End Results (SEER) analysis
-- Dr. Kelly Pendergrass: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC)
-- Roger Lyons, M.D.: Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
-- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology Research: Pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation Trial (RDT)
-- Guru Sonpavde, M.D.: Sunitinib malate is active and synergistic with cisplatin against human urothelial carcinoma in a preclinical model
About US Oncology Research
The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 528 physicians actively enrolling patients, 82 research sites, and is currently involved in 65 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer- fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.
About US Oncology, Inc.
US Oncology, headquartered in Houston, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.
According to the company's last quarterly earnings report, US Oncology is affiliated with 1077 physicians operating in 433 locations, including 90 radiation oncology facilities in 38 states.
Source: US Oncology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.